HER2 (Phospho_Tyr877) Antibody
- Known as:
- HER2 (Phospho_Tyr877) Antibody
- Catalog number:
- E011075-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- HER2 (Phospho_Tyr877) Antibody
Related genes to: HER2 (Phospho_Tyr877) Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 (Phospho_Tyr877) Antibody
Related articles to: HER2 (Phospho_Tyr877) Antibody
- Osimertinib is standard therapy for EGFR-mutant lung cancer, and HER2 amplification is a known resistance mechanism. We report HER2-positive breast cancer showing durable regression during osimertinib monotherapy for synchronous EGFR-mutated lung adenocarcinoma. Post-treatment analysis showed marked regression, HER2 amplification, no detectable EGFR, HER2, or PIK3CA mutations, ER/PgR negativity, preserved PTEN, and reduced proliferative activity. These findings suggest ERBB pathway inhibition may have contributed, although the mechanism remains speculative without functional validation. This hypothesis-generating observation describes unexpected breast cancer regression during osimertinib treatment. - Source: PubMed
Yasui HirotoshiHatasa MisakiOhara KoSano KaitoMori YasutakaShibata TomofumiFukui YasutakaOdate MitsuruArai YoshifumiFujii MasahiroMakino Yasushi - The HERIZON-GEA-01 trial in patients with advanced HER2-positive gastroesophageal adenocarcinoma demonstrated improved outcomes with the addition of the HER2xHER2-bispecific antibody zanidatamab to chemotherapy. The addition of tislelizumab, an anti-PD-1 antibody to chemotherapy and zanidatamab suggests additional survival improvements. HER2-targeting strategies leveraging spatially restricted target degradation and immune modulation are reframing HER2 approaches in HER2-positive gastroesophageal cancer. - Source: PubMed
Sundar RaghavKlempner Samuel J - Gastric adenocarcinoma (GAC) is characterized by molecular heterogeneity that limits early detection and targeted treatment. We applied weighted gene coexpression network analysis (WGCNA) to paired RNA-seq data from 119 GAC and peritumoral tissue (PTT) samples and identified six coexpression modules with distinct biological identities. Four modules were positively correlated with GAC and two were negatively correlated. Among the 30 hub genes evaluated, several outperformed established clinical biomarkers in accuracy. Specifically, SPARC (AUC = 0.89), COL3A1 (0.87), and COL1A2 (0.85) exceeded MUC5AC (0.76), VEGFA (0.68), and ERBB2 (0.64). Validation in the TCGA-STAD cohort confirmed concordant expression trends for MEblack (5/5 genes) and MEmagenta (4/5), with an overall fold-change correlation of ρ = 0.58 (p = 6.96 × 10⁻⁴). Immune deconvolution delineated two opposing microenvironmental axes, with an adaptive-immune-epithelial program (MEblack) associated with B-cell abundance, and a fibroblast-collagen program (MEmagenta) associated with cancer-associated fibroblast enrichment. DepMap CRISPR screening identified ribosomal hub genes as cell-intrinsic dependencies in gastric cancer cell lines. Among all hub genes, SPARC, COL3A1, COL1A2, GKN1, and GKN2 emerged as the potential biomarker candidates, with SPARC additionally showing a validated unfavorable prognostic association in STAD. - Source: PubMed
Publication date: 2026/08/10
Mourão Ronald Matheus da SilvaMoreira Fabiano CordeiroSilva Jéssica Manoelli Costa daCosta Daniel de Souza Avelar daSilva Valéria Cristiane Santos daVidal Amanda FerreiraMagalhães Leandro Lopes deAnaissi Ana Karyssa MendesDemachki SamiaBarra Williams FernandesAssumpção Paulo Pimentel de - Purpose To evaluate the added value of a synthetic radiomics model (S-Radiomics) that integrates topologic and Hessian-based features with traditional radiomic features for predicting a pathologic complete response (pCR) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Materials and Methods Patients with HER2-positive breast cancer from three centers were retrospectively included between January 2018 and January 2024. Patients from centers 1 and 2 ( = 201) were randomly assigned to training ( = 150) and internal testing ( = 51) sets, whereas patients from center 3 ( = 82) constituted external testing set I. An additional genomic set ( = 64, I-SPY 2) and external testing set II ( = 57, I-SPY 1) were used for independent validation. Multivariable logistic regression with all clinical variables was used to identify independent predictors ( < .05) and develop the clinical model, adjusting for potential confounders. Traditional radiomics model (T-Radiomics) and S-Radiomics were constructed. Performance was evaluated using area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification index, and survival analysis. Results A total of 404 female patients with HER2-positive breast cancer (mean age ± SD, 50 years ± 9) were included. The S-Radiomics outperformed the T-Radiomics on both the internal (AUC, 0.86 vs 0.78; = .37) and external test (AUC, 0.84 vs 0.73; = .11) sets, with improvements in the integrated discrimination improvement ( = .24 and .01) and net reclassification index ( = .21 and .01). Shapley additive explanations analysis revealed topologic features as the most important predictors. For center 1, survival analysis revealed longer disease-free survival in predicted responders ( = .02). Conclusion The S-Radiomics outperformed the T-Radiomics in predicting pathologic complete responses in patients with HER2-positive breast cancer. Radiogenomics, MRI, Breast, Human Epidermal Growth Factor Receptor 2, Breast Cancer, Neoadjuvant Chemotherapy, Pathologic Complete Response, Radiomics © RSNA, 2026. - Source: PubMed
Chen SiyiChen YongxinJin ChenZheng BingjieDing ShishenWeng ZijinTang WenjieLiu WeifengLin YihongKong QingcongZhou QianweiGuo Yuan - Ovarian carcinosarcoma (OCS) is a rare, aggressive tumor composed of both carcinomatous and sarcomatous components, typically associated with poor prognosis. Due to its rarity, the molecular characteristics, immune microenvironment, and optimal treatment of OCS remain unclear. This study aimed to characterize the genomic profiles, Trop-2 expression, and immune microenvironment of the carcinomatous and sarcomatous components of OCS separately, and to explore candidate therapeutic targets for this rare and aggressive tumor. - Source: PubMed
Sakamaki TomomiChiyoda TatsuyukiNakamura KoheiTakamatsu ReikaKawano RyutaroOchiai DaisukeJisaka MitsuyoTakahashi MioYoshimura TakumaKimura YumikoOki ShinyaSakai KensukeYoshihama TomokoNishihara HiroshiYamagami Wataru